Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy.

Rijlaarsdam, J. U.; Toonstra, Johan; Meijer, Otto W.M.; Noordijk, E.M.; Willemze, Rein

doi:10.1200/jco.1996.14.2.549

Cited by 125 publications

(58 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EFS at 5 years was at 60% for patients with localized disease vs 20% for those with diffuse disease (P Ͻ 0.01). In contrast to a previous report, 8 the prognosis for patients with PCLL of the B cell type localized on the leg was not poor in our series; however, this discrepancy may be explained by the fact that all our patients received chemotherapy and the patient population was small. Under polychemotherapy, these patients had a relapse rate of 50%, which is lower than the relapse rate observed after radiation therapy alone or monochemotherapy.…”

Section: Discussioncontrasting

confidence: 99%

“…Patients have been given various regimens from monochemotherapy to polychemotherapy or radiation therapy alone or associated with chemotherapy and experienced high relapse rates. [6][7][8] However, recent results have suggested that PCLL of the B cell type should not be treated with radiation therapy alone. 8 The use of polychemotherapy in this setting and results observed in nodal large-cell non-Hodgkin's lymphomas 8,14 led us to include PCLL patients in a protocol of polychemotherapy for high-grade lymphomas (LNH87).…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5] Furthermore, these PCLL may have clinical behaviors and prognoses different from those of primary node-based malignant lymphomas of the same histologic subtype. 3,6 Treatment has not yet been well-defined, comprising radiotherapy, polychemotherapy or both, 7,8 and no prospective studies have been performed in this rare and heterogeneous group of patients. After treatment, survival rates ranged from 30 to 80% and the worst prognosis is observed in CD30 − Tlarge cell lymphomas.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

et al. 1998

View full text Add to dashboard Cite

The objectives of this study were to evaluate the outcome after polychemotherapy for patients with primary cutaneous largecell lymphomas (PCLL) and to validate the recently proposed immunohistologic classification of cutaneous lymphomas. Among 140 patients with positive skin biopsies included in the LNH87 protocol (for treatment of aggressive lymphomas), 49 patients met the criteria of PCLL. Characteristics were: sex ratio M/F, 2.3; age 18 to 83 years (median, 52), peripheral lymph nodes, n = 22; diffuse disease, n = 12; median tumor size, 4.5 cm; elevated lactate dehydrogenase, n = 9; ECOG: 0/1, n = 49. Histology was: follicular center B cell, n = 23; B-lymphoblastic, n = 1; anaplastic large-cell lymphoma, n = 14 (T cell phenotype n = 8); CD30 ؊ T cell lymphoma, n = 11. All patients received polychemotherapy: under 70 years, ACVBP (three to four cycles and consolidation for 6 months) n = 25; mBACOD (eight cycles) n = 16; over 70 years, C(T)VP (six cycles) n = 8. Radiation therapy was not included in the protocol. With a median follow-up of 5 years, 24/49 patients had relapsed, with 20 skin relapses. Event-free (EFS) and overall survival (OS) at 5 years were, respectively, 50 and 77%. Significant adverse prognostic factors were: histology (CD30 ؊ T cell lymphoma) and diffuse cutaneous disease (Ͼ Ͼ Ͼ10% of skin). The presence of nodal involvement was only significant for EFS. When compared to 140 non-cutaneous lymphoma patients included in the same trial and fully matched for the main clinical characteristics, OS was similar. In conclusion, PCLL behaves like other localized B or T cell extranodal lymphomas with the same prognostic factors (LDH, ECOG, age) except for CD30 ؉ PCLL which have a very good prognosis.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Similarly, Piccinno et al [13] found a relapse rate of 68% following radiotherapy alone. In our study, excisional surgery was found to have a relapse rate of at least 50% in both DLBCL and MZL.…”

Section: Discussionmentioning

confidence: 99%

“…Systemic chemotherapy has also been used widely in the treatment of PCBCL [4,10,11,13,15,16]. The most appropriate form of chemotherapy is not known, but CHOP has been found to be superior to COP (cyclophosphamide, vincristine, prednisolone) in some studies [13,[17][18][19]. This form of therapy has traditionally been used for patients with multifocal or extensive lesions as they are considered to be at higher risk of developing extracutaneous disease [11,16].…”

Section: Discussionmentioning

confidence: 99%

Cutaneous B‐cell lymphoma: Pathological spectrum and clinical outcome in 51 consecutive patients

Sah¹,

Barrans²,

Parapia³

et al. 2004

American J Hematol

View full text Add to dashboard Cite

The clinical behavior and optimal treatment of patients presenting with skin infiltration by B-cell lymphoma have not been established. To clarify this we assessed the clinical and laboratory features of 51 patients presenting with cutaneous infiltration by B-cell lymphoma. Follow-up data was available for 46 patients with a median age of 68 years (range 16-89 years) and a median follow-up of 32.5 months (range 5-123 months). Thirty-three of 51 (65%) patients had diffuse large B-cell lymphoma (DLBCL), and 15/51 (29%) had marginal zone lymphoma (MZL). The remaining 3 patients had follicular lymphoma, CLL, and post-transplant lymphoproliferative disease. Of the 33 patients with DLBCL, follow-up was available in 29; 24/29 (83%) had primary cutaneous disease, which was unifocal in 17/24 (71%). Following treatment, 8/24 (33%) of the primary cases relapsed. Of the 8 who relapsed, 7 had received local forms of treatment only. Follow-up data was available in 14/15 patients with MZL. 11/14 (79%) had primary cutaneous disease, which was unifocal in 8 (73%). Following treatment, 4 of these cases relapsed (36%); all had received local therapy only. It is evident from this study that a significant proportion (~20%) of patients who present with cutaneous infiltration by B-cell lymphoma have systemic disease. Staging is therefore mandatory in these patients. Approximately 1/3 patients with primary cutaneous DLBCL or MZL ultimately relapse, and relapse rates appear higher in thosepatients receiving local therapy only. Systemic or combined modality therapy may therefore be the most appropriate treatment at presentation. This should be assessed prospectively in randomized trials. Am.

show abstract

Results of Radiotherapy in 153 Primary Cutaneous B-Cell Lymphomas Classified According to the WHO-EORTC Classification

Senff¹

2007

Arch Dermatol

112

View full text Add to dashboard Cite

show abstract

Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy.

Cited by 125 publications

References 4 publications

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

Cutaneous B‐cell lymphoma: Pathological spectrum and clinical outcome in 51 consecutive patients

Results of Radiotherapy in 153 Primary Cutaneous B-Cell Lymphomas Classified According to the WHO-EORTC Classification

Contact Info

Product

Resources

About